- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies
Panelists discuss how managing patients with mild cognitive impairment using amyloid-targeting therapies faces significant barriers including limited healthcare infrastructure for complex diagnostic testing and monitoring, insufficient insurance coverage and high out-of-pocket costs, challenges in patient selection and risk stratification, logistical hurdles of regular infusions and imaging, shortage of specialists in many regions, and the need for comprehensive patient education about realistic treatment expectations.
EP: 1.Strategies for Enhancing Early Diagnosis and Implementation of Disease-Modifying Therapies in Alzheimer Disease
EP: 2.Advancing Early Alzheimer Diagnosis: Best Practices for Timely Screening and Detection
EP: 3.Care Pathways for Nonspecialist Providers When Evaluating Patients With Potential Mild Cognitive Impairment
EP: 4.Empowering Nonspecialist Providers and Addressing Gaps in Dementia Care: How Tools and Biomarkers Can Help
EP: 5.Factors to Evaluate When Selecting a Combination of Screening Assessments and Tests for Detecting Alzheimer Disease
EP: 6.From Time Constraints to Reimbursement: Addressing Key Hurdles in Cognitive Screening for Alzheimer Disease
EP: 7.Expanding Access to Alzheimer Disease Care: Leveraging Referral Networks and Telemedicine for Patients in Underserved Areas
EP: 8.Amyloid-Targeting Therapies in Alzheimer Disease: Mechanisms of Action, Efficacy, and Safety Considerations
EP: 9.Real-World Implications of Changes in CDR-SB Score in Patients Receiving Amyloid-Targeting Therapy
EP: 10.Patient Selection for Amyloid-Targeting Therapies: Key Characteristics and Considerations
EP: 11.Understanding the Hesitancy to Prescribe Amyloid-Targeting Therapies for Patients With Alzheimer Disease
EP: 12.Navigating the Risk-Benefit Conversation: Discussing Amyloid-Targeting Therapies With Patients and Caregivers
EP: 13.Criteria for Discontinuing Treatment With an Amyloid-Targeting Therapy
EP: 14.Strategies for Clinicians When Developing Protocols for Managing ARIA
EP: 15.Key Barriers in Managing Patients With Mild Cognitive Impairment Using Amyloid-Targeting Therapies
EP: 16.Access to Diagnostic Tests and Coverage for Amyloid-Targeting Therapies: Payer Considerations
EP: 17.Addressing Concerns About the Financial Impact of Amyloid-Targeting Therapies
EP: 18.Final Thoughts Alzheimer Disease Care
Video content above is prompted by the following:
Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL
July 16th 2025Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).
Read More
